Etiopathogenesis and treatment strategies of oral submucous fibrosis

Abstract

The etiopathogenesis and management of oral submucous fibrosis has been the subject of controversy ever since Schwartz first described the condition in 1952. Population estimates of OSMF indicated that 2.5 million people were affected worldwide. This number has risen to 5 million on the Indian subcontinent itself. It calls for the need to treat such a critical precancerous condition with aggressive steps. Before one goes to treat this disease it is required to have a look at all the modalities tried so far in the literature. This article aimed at the same signature facts of the etiopathogenesis and various treatment modalities of OSMF.